A(3) adenosine receptor ligands: history and perspectives.
about
Adenosine receptors and asthma in humansStructure-Bioactivity Relationships of Methylxanthines: Trying to Make Sense of All the Promises and the DrawbacksPharmacological characterization of adenosine receptors in PGT-beta mouse pineal gland tumour cellsDesign and synthesis of N(6)-substituted-4'-thioadenosine-5'-uronamides as potent and selective human A(3) adenosine receptor agonists.Discovery of New Human A(2A) Adenosine Receptor Agonists: Design, Synthesis, and Binding Mode of Truncated 2-Hexynyl-4'-thioadenosine.Design and synthesis of truncated 4'-thioadenosine derivatives as potent and selective A3 adenosine receptor antagonists.Structure-activity relationships of truncated C2- or C8-substituted adenosine derivatives as dual acting A₂A and A₃ adenosine receptor ligands.Synthesis and Binding Affinity of Homologated Adenosine Analogues as A3 Adenosine Receptor Ligands.The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure.Structure-activity relationships of truncated adenosine derivatives as highly potent and selective human A3 adenosine receptor antagonists.IB-MECA and cardioprotection.Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonistsRegio- and stereoselective synthesis of truncated 3'-aminocarbanucleosides and their binding affinity at the A3 adenosine receptor.Design, synthesis, and binding of homologated truncated 4'-thioadenosine derivatives at the human A3 adenosine receptorsPyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure-activity profile.Synthesis of (R)-3,4-dihydro-2H-pyran-2-carboxaldehyde: application to the synthesis of potent adenosine A(2A) and A(3) receptor agonist.Synthesis and pharmacological characterization of [(125)I]MRS1898, a high-affinity, selective radioligand for the rat A(3) adenosine receptor.Synthesis of 2-chloro-N6-substituted-4'-thioadenosine-5'-N, N-dialkyluronamides as potent and selective A3 adenosine receptor antagonists.Adenosine neuromodulation and traumatic brain injury.Synthesis and anti-renal fibrosis activity of conformationally locked truncated 2-hexynyl-N(6)-substituted-(N)-methanocarba-nucleosides as A3 adenosine receptor antagonists and partial agonists.The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches.Design, synthesis, and anti-tumor activity of 4'-thionucleosides as potent and selective agonists at the human A3 adenosine receptor.Stereoselective synthesis of 1'-functionalized-4'-thionucleosides.Pyrazin-2(1H)-ones as a novel class of selective A3 adenosine receptor antagonists.A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.Structure-Affinity Relationships and Structure-Kinetics Relationships of Pyrido[2,1-f]purine-2,4-dione Derivatives as Human Adenosine A3 Receptor AntagonistsPyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes.Chalcone-based derivatives as new scaffolds for hA3 adenosine receptor antagonists.Theophylline exhibits anti-cancer activity via suppressing SRSF3 in cervical and breast cancer cell lines.Synthesis and adenosine receptors binding affinities of a series of 3-arylcoumarins.Targeting adenosine receptors with coumarins: synthesis and binding activities of amide and carbamate derivatives.Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function.Navigating in chromone chemical space: discovery of novel and distinct A3 adenosine receptor ligands
P2860
Q24644125-2D8A118B-7B69-4F3D-9F8B-24D0E558D108Q26740559-D64E7146-D0E3-4DD5-BFB2-FA8E335CA7C3Q28346743-001972B9-F38D-4919-9461-E65F9299CA7DQ33554208-5C6B7DBC-DEE4-42D0-BAB6-41A804806B6AQ34536571-1DFD8426-C372-4EB5-9C39-B5402E1E0F8EQ34990852-2C683B70-909B-441D-B620-11987CDD6699Q35698610-F44C0356-4FF3-4614-B701-D2809E7C0DBFQ35774202-CCF156EC-FE52-40D8-ACD2-431CD48CE79BQ36317172-27B7D0AE-A4C0-4930-82AC-B0AB89D6917FQ36627486-EA0ECFB2-7917-47A5-8D12-02C5F1D32E0CQ36703832-267DB0FD-9818-4480-B823-4F32CD3275BCQ36740173-EC0ED89D-52F2-435D-B1A9-77FDC79380EBQ36740193-90381482-E899-41F3-99B5-41970DCD519AQ37048000-6D350BAE-57BB-4E9F-AFE2-06E118649079Q37135506-A7B7D137-8D70-4E8D-AB64-FC0C20260AE9Q37185339-7E325D88-BE3D-458C-A0C3-BE081BF484BDQ37291606-E7167868-4E02-4ACD-B07E-F2EEAC0F54E2Q37356590-23A10C3B-0562-445D-9C3E-C44468758A7CQ37402676-FD0CD56B-D54F-424C-AEB0-050018FCF699Q37637798-89435EDD-2F47-415B-A1ED-4B500F23A020Q37957791-0D3C5434-7CE7-426A-BF21-F1C3EAF7FB0CQ38503177-3F49D703-3DAA-4EDC-A827-5C0D181044F2Q38503252-47A7CF81-AECD-43E5-8A6B-9D8321C469E4Q38979023-D810FBC1-F953-4877-A92E-C69AD36F984EQ39418010-9A269DF3-1E59-407C-9831-3872D2A1D517Q41722014-3134461D-D0AC-4697-B30B-3F77830C8D82Q43049495-D874A99B-9808-4053-9352-1F1130976C30Q43944774-22CA6EC2-84F5-488F-B1FB-5CCA28C89189Q47136712-DEE16092-70A4-41BC-809B-1B4E232C4F26Q51751563-571426EE-A9A4-4EF4-9CAE-1358CA5F7420Q51755796-A32E0571-8833-46F3-A7A7-714537E61C3CQ53567783-032B667A-4013-462F-8C1F-952267C0C8B7Q56990903-363791F7-0507-4273-82F0-FCF727E81917
P2860
A(3) adenosine receptor ligands: history and perspectives.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
A(3) adenosine receptor ligands: history and perspectives.
@ast
A(3) adenosine receptor ligands: history and perspectives.
@en
type
label
A(3) adenosine receptor ligands: history and perspectives.
@ast
A(3) adenosine receptor ligands: history and perspectives.
@en
prefLabel
A(3) adenosine receptor ligands: history and perspectives.
@ast
A(3) adenosine receptor ligands: history and perspectives.
@en
P2093
P1476
A(3) adenosine receptor ligands: history and perspectives.
@en
P2093
Baraldi PG
Cacciari B
Romagnoli R
Spalluto G
P2860
P304
P356
10.1002/(SICI)1098-1128(200003)20:2<103::AID-MED1>3.0.CO;2-X
P577
2000-03-01T00:00:00Z